Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · IEX Real-Time Price · USD
8.17
-1.31 (-13.82%)
At close: Jul 19, 2024, 4:00 PM
8.02
-0.15 (-1.84%)
Pre-market: Jul 22, 2024, 7:07 AM EDT

Adverum Biotechnologies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2012
Revenue
03.607.500.25
Upgrade
Revenue Growth (YoY)
------84.49%
Upgrade
Gross Profit
03.607.500.25
Upgrade
Selling, General & Admin
48.5649.9257.8664.4444.6428.38
Upgrade
Research & Development
72.0377.6899.2889.1873.3140.42
Upgrade
Operating Expenses
120.59127.59157.14153.62117.9568.8
Upgrade
Operating Income
-120.59-123.99-157.14-146.12-117.95-68.55
Upgrade
Other Expense / Income
-6.6-5.75-2.67-0.58-1.56-4.06
Upgrade
Pretax Income
-113.99-118.24-154.46-145.54-116.39-64.49
Upgrade
Income Tax
-1.1-1.080.0701.110
Upgrade
Net Income
-112.9-117.17-154.54-145.54-117.51-64.49
Upgrade
Shares Outstanding (Basic)
1610101096
Upgrade
Shares Outstanding (Diluted)
1610101096
Upgrade
Shares Change
64.30%1.58%1.24%15.14%32.83%4.44%
Upgrade
EPS (Basic)
-10.20-11.60-15.60-14.80-13.80-10.10
Upgrade
EPS (Diluted)
-10.20-11.60-15.60-14.80-13.80-10.10
Upgrade
Free Cash Flow
-92.55-91.71-119.91-122.95-91.14-68.42
Upgrade
Free Cash Flow Per Share
-5.62-9.10-12.08-12.54-10.70-10.67
Upgrade
Gross Margin
-100.00%-100.00%-100.00%
Upgrade
Operating Margin
--3444.19%--1948.29%--27418.00%
Upgrade
Profit Margin
--3254.58%--1940.53%--25794.40%
Upgrade
Free Cash Flow Margin
--2547.50%--1639.39%--27366.80%
Upgrade
EBITDA
-96.84-99.57-143.89-140.9-112.24-62.91
Upgrade
EBITDA Margin
--2765.89%--1878.60%--25165.20%
Upgrade
Depreciation & Amortization
17.1618.6710.574.654.161.57
Upgrade
EBIT
-113.99-118.24-154.46-145.54-116.39-64.49
Upgrade
EBIT Margin
--3284.53%--1940.53%--25794.40%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).